fixed dose combination [Bioanalytics]

posted by Ohlbe – France, 2015-03-09 20:00 (3713 d 12:28 ago) – Posting: # 14556
Views: 5,162

Dear Avinash,

Selectivity is a must, of course. Long term stability in matrix is required by the EMA guideline (and by the FDA through '483s), though there is a lot of debate around the scientific basis for this.

I would also suggest to check there is no matrix effect issue (ion suppression form analyte A due to analyte B, and vice-versa). I think having one run for precision and accuracy for each analyte in presence of a high concentration of the other analyte would also be good.

Regards
Ohlbe

Complete thread:

UA Flag
Activity
 Admin contact
23,424 posts in 4,927 threads, 1,671 registered users;
107 visitors (0 registered, 107 guests [including 5 identified bots]).
Forum time: 09:29 CEST (Europe/Vienna)

Freedom is always and exclusively
freedom for the one
who thinks differently.    Rosa Luxemburg

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5